Your Source for Venture Capital and Private Equity Financings

Massinvestor/VC News Daily

VC-funded Company:

Simcha Therapeutics

Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simcha's lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020. A Phase 1 trial is expected to be launched in the first half of 2021. Simcha was founded by Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.

Key Contact
Name
Aaron Ring, M.D., Ph.D.
Title
Founder
E-Mail
Funding Events

Date
Amount
Type
Investors
06/25/20 $25,000,000 Series A Connecticut Innovations
Sequoia Capital
WuXi AppTec